EV20/NMS-P945

N/A

Report date: 2024/02/05 14:03:42

Base Information

Drug NameEV20/NMS-P945

Drug Alias NameEV20/NMS-P945

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > NMS-P528 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists

TargetsReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMedia Pharma SRL

China Registration ClassN/A

Develop Information

Active CompaniesMedia Pharma SRL

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A